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Abstract
The long-term neuropsychological, cognitive, and neurobiological effects of the severe acute
respiratory syndrome (SARS-CoV-2) in survivors with milder symptoms are still poorly
understood. In this thesis we evaluated cognitive and psychological changes approximately
five weeks after a wide range of symptoms in COVID-19 illness and determined whether
advanced diffusion magnetic resonance imaging measures within subcortical brain structures
of the limbic system were related to neurological, respiratory, psychiatric, and gastric
symptoms experienced during the acute phase of illness. Cognitive and neuropsychological
evaluations were performed in 45 participants who experienced neurological symptoms
during the acute phase of COVID-19 illness. Participants also underwent a 7 Tesla MRI
neurological exam on the same day. The group showed a significant reduction in attention
compared to a normative population, but no differences in other cognitive domains. Although
white matter hyperintensities were visible on fluid attenuated inversion recovery (FLAIR)
images in 22 of 43 participants consistent with small vessel ischemic disease and migraine,
this incidence is consistent with that expected in a normative population. Participants were
divided into groups based on the presence or absence of symptoms at their acute illness from
the medical history collected over the phone or in-person during recruitment. No differences
were observed in subcortical brain structure volumes when comparing participants between
subgroups. Differences in advanced diffusion metrics were observed within several
subcortical structures (p<0.0036, Bonferroni corrected Mann-Whitney U-test) when
comparing groups suggesting subtle tissue changes in several regions that were mostly
related to respiratory and gastric symptoms. There were no strong associations between
diffusion measurements and attention. Future studies should follow participants
longitudinally to determine whether the observed changes persist.
Keywords
SARS-CoV-2, COVID-19, MRI, cognition, limbic system, diffusion, magnetic resonance
imaging, diffusion tensor imaging, DTI

ii

Summary for Lay Audience
We have struggled with coronavirus disease 2019 or COVID-19 since December 2019. This
virus led to a pandemic because it has spread worldwide and affected many people. It
impacted the world from a health and economic perspective and motivated scientists from all
over the world to investigate the illness to minimize the risks to future human health.
Although COVID-19 starts by infecting the respiratory system, it causes a range of
symptoms and affects many different organs, including brain. In this thesis, we investigate
the long-term cognitive effects and imaging changes of COVID-19 infection in the brain
within 45 patients with mostly mild symptoms after they have recovered from the respiratory
symptoms. We used a very high magnetic field strength MRI scanner to acquire images of
the brain for this study to better understand subtle changes in brain tissue.
To evaluate cognition, we compared COVID-19 survivors in the study using standardized
questionnaires with data from a normative group that included healthy adolescents and
adults. The results showed that patients who recovered from COVID-19 illness had attention
deficits. In some patients, we observed minor changes in the MRI scans indicating some
disease processes, but these were mostly consistent with what we would expect in a control
group of people at the same age. Since we did not have access to baseline brain imaging, we
cannot say that these abnormalities are directly related to the COVID-19 infection.
We also used more advanced diffusion MRI techniques to investigate microstructural
changes in the brain.

Here, we did find some changes within the brain tissue when

comparing groups with and without specific symptoms that the patients experienced during
their acute illness.
In summary, this study found changes in attention about five weeks (13854 days) after
COVID-19 illness and subtle differences in some measures of tissue microstructure in the
brain. Larger studies are needed to confirm these findings and to determine if these changes
persist.
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Chapter 1

1

Introduction
1.1

Research Motivation and Objectives

Due to the novelty of the coronavirus disease of 2019 (COVID-19), the long-term
consequences of the infection on respiratory function and its impact on other organs
including the brain requires further investigation. The aim of the work presented in this
thesis was to understand the long-term cognitive and neurobiological effects of COVID19 in patients with mild infection who experienced neurological symptoms, after the
respiratory symptoms had resolved.

1.2
Brain Subcortical Structures and the Limbic
System
The complex and diverse range of neurological symptoms encountered by patients
following COVID-19 infection suggests a broad potential impact of the virus in the brain.
Although the brain may be globally affected by SARS-CoV-2 infection and the
subsequent cytokine storm, the limbic system may be particularly vulnerable to damage.
The limbic system is a set of structures on both sides of the thalamus under the cerebrum.
It includes the hypothalamus, the hippocampus, the amygdala, and several other nearby
areas. The limbic system is primarily responsible for emotion and the formation of
memories.

Figure 1-1: The limbic system. Lateral view of the brain showing some of the limbic
system structures. Image by Marieb et al. [173].
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1.2.1

Hypothalamus

The hypothalamus is located below the thalamus on both sides of the third ventricle. The
hypothalamus is mainly responsible for homeostasis which is the process of returning
something to some set point. It is responsible for regulating hunger, thirst, response to
pain, levels of pleasure, anger, and aggressive behavior. It also regulates the functioning
of the autonomic nervous system that controls blood pressure, breathing and response to
emotional circumstances. The hypothalamus receives inputs from several sources. For
example, it gets information from the limbic system and the olfactory nerves that helps
regulate eating.

1.2.2

Hippocampus

The hippocampus resembles a horn that curves back from the amygdala. It is an
important structure involved in the conversion of short-term memories into long-term
memories. If the hippocampus is damaged the formation of new memories will be
impaired.

Hippocampal damage is for example, an important component in the

progression of Alzheimer’s disease.

1.2.3

Amygdala

The amygdala is an almond-shaped structure full of neurons found on either side of the
thalamus at the lower end of the hippocampus. It is important in experiences of anger and
fear. The amygdala impacts on the formation of memories of experiences based on
emotional impact.
Beyond the hypothalamus, hippocampus, and amygdala there are other areas near the
limbic system that are connected to it including the cingulate gyrus, ventral tegmental
area, the basal ganglia, and the prefrontal cortex.
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1.2.4

The Basal Ganglia

The basal ganglia include the caudate nucleus, the putamen, the globus pallidus and the
nucleus accumbens. The basal ganglia are adjacent to the thalamus and connected with
the cortex. All these structures exist bilaterally, one set on each side of the central
septum. They are involved in repetitive behaviors, reward experience and focusing
attention.

Figure 1-2: Basal ganglia. Three-dimensional view of the basal ganglia, deep in the
cerebrum. Image by Marieb et al. [173]

1.2.5

The Caudate

The caudate nucleus is a C-shaped structure in the center of the brain. It is divided into
three parts: the head, body, and tail. It plays a role in repetitive function, and it is
involved in mental disorders including attention deficit and hyperactivity disorder
(ADHD) [87].

1.2.6

The Putamen

The putamen is a subcortical structure that forms the dorsal area of the basal ganglia. It is
responsible for reinforcement learning and motor control including speech articulation
[88].
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1.2.7

The Globus Pallidus

The globus pallidus (GP) or pallidum is a triangular mass of cells medial to the putamen.
The main function of the GP is to control conscious and proprioceptive movements. It
receives information from multiple structures [89]. The involvement of the GP has
demonstrated in several different disorders such as obsessive-compulsive disorders
(OCD), ADHD, Parkinson’s, and Huntington’s [89]– [91].

1.2.8

The Nucleus Accumbens

The nucleus accumbens is the most inferior part of the striatum that is connected mainly
to the limbic system. Together with the prefrontal cortex and amygdala it consists of a
part of the cerebral circuit that regulates functions associated with effort. It provides
emotional and behavioral components of feelings. It interferes between motivation and
action and plays a key role in food intake, sexual behavior, reward-motivated behavior,
stress related behavior, and substance-dependence. It also involved in several cognitive
and emotional functions, and some severe psychiatric disorders such as depression,
schizophrenia, addiction, attention deficit disorders and other anxiety disorders, and posttraumatic stress disorder (PTSD) [92].

1.3

Magnetic Resonance Imaging (MRI)

Magnetic resonance imaging is based on the nuclear magnetic resonance (NMR)
phenomenon, which is dependent on the property of nuclear spin. NMR involves
measuring emitted energy from atomic nuclei placed in a magnetic field following
excitation by radio frequency (RF) waves.

Hydrogen is the most abundant element in

the human body that can generate an MRI signal [95].

1.3.1

Ultra-high field (UHF) MRI

From the initial grainy images of the human brain, technical developments in MR
imaging techniques and improved hardware now produce unique and very detailed
images of brain anatomy, function and metabolism that are an integral component of
neurologic evaluation [96]. The growing interest in ultra-high field MRI is related to the
potential to improve clinical results with better quality images due to increased signal-to-
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noise ratio (SNR). SNR increases with the magnetic field strength of the MRI scanner
with potential for higher spatial resolution and contrast compared to lower field strengths
(1.5T or 3T) to improve lesion detection [97]. A downside of the increase in field
strength is the introduction of non-uniformities in the transmit field radiofrequency that
can compromise image contrast uniformity [98]. Ultra-high field MRI applications in
neuroimaging include detection of changes in cortical structures like microinfarcts and
cortical plaques in multiple sclerosis, imaging of the hippocampus with high spatial
resolution, iron accumulation, and vascular imaging [97]. In the study presented in this
thesis, five major types of imaging contrasts were obtained in participants as described
below.

1.3.2

Magnetization prepared-rapid gradient echo (MPRAGE)

MPRAGE consists of a non-selective (180) inversion pulse followed by a series of rapid
acquisition of gradient echoes obtained at short echo-times (TE) and small flip angles that
makes it the most common sequence for 3D-T1-weighted imaging. MP2RAGE by
comparison includes two gradient readouts between inversion pulses.
The MPRAGE sequence is one of the most common T1-weighted (T1-w) image
acquisition for structural brain imaging that provides high contrast between grey and
white matter specially for brain segmentation. The self-bias-field corrected MP2RAGE is
used at 7T to improve the signal inhomogeneity [98] by combining the data from both
readouts.

1.3.3

Fluid attenuation inversion recovery (FLAIR)

FLAIR is an MRI sequence preceded by an inversion pulse that incorporates an inversion
recovery (IR) period to null fluids. In brain imaging, better detection of periventricular
WM hyperintensities is possible when cerebrospinal fluid (CSF) is nulled within an
image [99]. For optimal suppression, an inversion time is selected that corresponds to the
time needed for the CSF magnetization to reach a null point after inversion. At that point
there is no longitudinal magnetization from CSF to contribute to subsequent imaging.
When an excitation pulse is applied, since there is no longitudinal component from the
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CSF, no transverse magnetization is generated after excitation and the CSF signal is
minimized [99].

1.3.4

3D-Gradient echo (GRE)

Gradient echo (GRE) is a fast MRI technique. The small flip angle that is employed in
GRE, allows for the use of a short repetition time (TR), which can decrease scan time.
Thus, GRE can be used for rapid volumetric imaging of thin continuous slices (threedimensional imaging) without cross-talk [100].
The use of gradient echoes (rather than 180 refocusing pulses) in GRE imaging results
in greater dephasing of spins and makes this pulse sequence sensitive to magnetic field
distortions. As a result, GRE is very effective in identifying microhemorrhages [100].

1.3.5

3D-time-of- flight (TOF) angiography

Time-of- flight (TOF) MR angiography (MRA) is a common non-invasive method used
to visualize the human vascular system. Contrast is based on flow-related enhancement
using 2D or 3D gradient echo techniques [100]. 3D-TOF MRA has higher SNR
compared to 2D since the signal is acquired from a larger volume. It also is capable of a
higher spatial resolution [100]. TOF-MRA at high field strength (e.g. 7T) is advantageous
over lower field MRI because T1 relaxation time constants increase at high field and a
better vessel to background contrast can be achieved [101]. Furthermore, as mentioned
before, UHF scanners provides higher SNR and spatial resolution [97] that enhance the
sensitivity of the TOF angiogram and consequently the detection of vascular
abnormalities [102].

1.3.6

Advanced diffusion MRI (dMRI)

Diffusion refers to the movement of water molecules in the extracellular space due to
random thermal motion. The motion is restricted either by cellular boundaries such as
ligaments and membranes or pathology. The net displacement of molecules diffusing
across an area of tissue per second is the apparent diffusion coefficient (ADC). If
diffusion is restricted, ADC is low, while in areas of free diffusion it is high.
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In diffusion weighted imaging (DWI), the sequence is sensitized to this motion by
applying two gradients on either side of a 180 RF pulse. In diffusion imaging, normal
tissue with high ADC has lower signal intensity compared to abnormal tissue, which may
have low ADC. The diffusion of water is often restricted in pathology.

1.3.6.1

Diffusion tensor imaging (DTI)

DTI is a quantitative MRI method to measure water movement within the tissue
microstructure [103]. DTI is an extended form of DWI, that measures water diffusion in
three gradient directions for an estimation of the trace of the diffusion tensor [104]. It is
the most established technique for the non-invasive investigation of the CNS
microstructure [105]. Microstructural features that affect the diffusion rate of water
include cell size, shape, density, orientation and the presence of membranes and barriers
[106], [107].
In DTI the signal is dependent on the magnitude and direction of water diffusion. Each
voxel is fit with an ellipsoid that is represented by three unit vectors (i =direction) and
their corresponding length (i =magnitude). There are two commonly derived quantitative
measures from the tensor that inform us about cellular microstructure: fractional
anisotropy (FA) and mean diffusivity (MD). To obtain these measures, the diffusion
MRI data is fitted to the diffusion tensor model [108]. We use the ellipsoid components
to describe water diffusion.

1.3.6.1.1

Mean diffusivity (MD)

MD is a measure of the average molecular motion independent of any tissue
directionality and it is affected by cellular size and integrity [109]. The MD is defined in
the equation provided below.
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Mean Diffusivity (MD) = (1+2+3)/3
1.3.6.1.2

Fractional anisotropy (FA)

FA is a measure of anisotropic water diffusion and reflects the degree of directionality of
cellular structures (e.g. fiber tracts) and their structural integrity [104]. This value is
obtained from the magnitude of the diffusion tensor due to anisotropy [110]. In a purely
isotropic media, FA would be 0 and with increasing anisotropy the value tends to 1 [104].

2

2

√
1 (𝜆1 −𝜆2) + (𝜆2 −𝜆3) +(𝜆1−𝜆3)
√
𝐹𝐴 =
2
√𝜆2 +𝜆2 +𝜆2
1
2
3

1.3.6.1.3

2

Microscopic fractional anisotropy (FA)

In some situations, conventional DTI is unable to distinguish between true
microstructural complexity and neuron fiber orientation dispersion. This limitation can
reduce specificity for disease in brain regions that have crossing or fanning axons [111].
Microscopic anisotropy (A) is an anisotropy metric that is independent of reference
frame and orientation dispersion. Microscopic fractional anisotropy (FA) is a
normalized variation of A that removes the dependence on compartment size [112].

1.3.7

Diffusion kurtosis imaging (DKI)

Diffusion kurtosis imaging is a method to quantify water diffusion in biologic tissue that
is non-Gaussian. It is an extension of conventional diffusion-weighted imaging that
requires a modified postprocessing method and higher b values[113]. The reason that
DKI provides specific measures of tissue structure is because tissue structure is
responsible for the deviation of water diffusion from Gaussian behavior, which is
typically seen in homogenous solutions. This approach provides an estimate of both the
Gaussian distribution (diffusion tensor metrics) and the deviation from this Gaussian
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distribution (diffusion kurtosis metrics), which makes the method potentially more
sensitive to visualize microstructural changes [113].

1.4

Cognitive Assessments

Standardized cognitive assessments provide a means to compare cognitive performance
in people over time, or in people with neurological conditions or diseases. Although
useful for assessing general changes, cognitive assessments can be variable and impacted
by factors such as sleep, nutrition, fatigue, and the conditions of test administration. A
series of standardized tests were used in this thesis to measure cognitive performance and
mental state as described below.

1.4.1

The Repeatable Battery for the Assessment of
Neuropsychological Status (RBANS)

The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) is a
brief test that measures attention, language, visuospatial/constructional abilities, and
immediate and delayed memory. The test has 12 subtests and takes about 20 to 30
minutes to complete, which maximizes patient cooperation and minimizes the effects of
fatigue on patient performance. Although initially the RBANS was primary used for the
assessment of dementia in older populations, its potential for screening neurocognitive
status in younger patients became apparent and standardized data was modified to include
normative reference data from ages 12 to 89 [114].

The normative scores were

developed using a stratified, national sample of 690 healthy adolescents and adults. The
RBANS can measure discrete neuropsychological domains by producing scaled scores.
Furthermore, alternate forms make it possible to evaluate disease progress or outcomes
following treatment with therapeutics or rehabilitation [114].
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1.4.1.1

Organization of the Scale

The RBANS tests five different domains (Figure 3). The score for each of the 12 subtest
contributes to one of these five domains. A total score can be computed by combining the
five domain scores.

Figure 1-3: The five domains and the subtests that contribute to each domain [114].

1.4.2

The Montreal Cognitive Assessment (MoCA)

The Montreal Cognitive Assessment (MoCA) is a rapid screening instrument for mild
cognitive dysfunction. Mild cognitive impairment (MCI) is an intermediate clinical state
between normal cognitive aging and dementia, which in many cases precedes dementia
[115]. This tool assesses different cognitive domains including attention and
concentration, executive function, memory, language, visuoconstructional skills,
conceptual thinking, calculations, and orientation.
It is a one-page test (available at www.mocatest.org) administered in 10 minutes with a
maximum total score of 30 points. A score of 26 or above is considered normal. The
MoCA-BLIND test is an adapted version of the original MoCA test that contains the
same items except for those that require visual abilities, so it can be administered over the
phone. This test takes approximately 5-10 minutes to complete with a total score of 22.
A score of 19 or above is considered normal. (www.mocatest.org)
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1.4.3

The Telephone Interview for Cognitive Status (TICS)

The Telephone Interview for Cognitive Status (TICS) is a global mental status test that
can be administered over the phone or in-person [116]. It measures orientation,
concentration, short-term memory, language, praxis, and mathematical skills. The test has
excellent sensitivity and specificity in differentiating patients with Alzheimer’s disease
from normal and high test-retest reliability in this population [116].

1.4.4

Columbia Suicide Severity Rating Scale (CSSRS)

Suicide is one of the most important public health issues in many countries. Suicide risk
increases in people with mental disorders or impulsive behavior, and those facing
stressful situations [117]. The Columbia Suicide Severity Rating Scale (C-SSRS) has
been widely used for assessment of suicidality by several agencies such as Health Canada
and is available for free at www.cssrs.columbia.edu [117]. This scale assesses the worst
point and lifetime severity and intensity of suicidal ideation and the type and lethality of
suicidal behavior [117]. Selected items in the survey predict social risk including
preparatory activity [118].

1.4.5

Diagnostic and Statistical Manual of mental disorders, Fifth
Edition (DSM-5)

The Diagnostic and Statistical Manual of mental disorders, fifth edition (DSM-5) is the
2013 update to the Diagnostic and Statistical Manual of mental disorders published by
the American Psychiatric Association. It provides guidelines for clinical evaluations at
the time of initial patient visit and for monitoring treatment progress. The PatientReported Outcomes Measurement Information System (PROMIS) is a collection of
person-centered measures of physical, mental, and social health [119] used to capture
symptoms associated with mental disorders. The following measures were included in
this thesis: DSM-5 Self-Rated LEVEL 1 Cross-Cutting Symptom Measure-Adult,
LEVEL 2 Somatic Symptom-Adult Patient (adapted from the Patient Health
Questionnaire Physical Symptoms [PHQ-15]), LEVEL 2 Sleep Disturbance-Adult
(PROMIS-Sleep Disturbance-Short Form), LEVEL 2 Depression-Adult (PROMIS
Emotional Distress-Depression-Short Form), LEVEL 2 Anxiety-Adult (PROMIS
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Emotional Distress-Anxiety-Short Form), LEVEL 2 Anger-Adult (PROMIS Emotional
Distress-Anger-Short Form), Severity of Post-traumatic Stress Symptoms-Adult
(National Stressful Events Survey PTSD Short Scale [NSESSS]), and the Severity of
Acute Stress Symptoms-Adult (National Stressful Events Survey Acute Stress Disorder
Short Scale [NSESSS]).

1.5

SARS-CoV-2

Coronaviruses are a diverse group of viruses that infect animals and humans. In 2002 and
2012 two different coronaviruses caused fatal respiratory illnesses in humans and made
coronaviruses a major public health concern in the twenty-first century [1] . In late
December 2019 a novel severe acute respiratory syndrome coronavirus (SARS-CoV-2)
emerged in the city of Wuhan, China and spread quickly causing a global pandemic.
SARS-CoV-2 is a highly transmissible coronavirus that can cause acute respiratory
disease in humans [2] with a wide range of symptoms including fever, fatigue, cough and
chest discomfort with dyspnea and bilateral lung infiltration in severe cases [3].
Additional symptoms may include sputum production, pneumonia, headache,
hemoptysis, diarrhea, anorexia, sore throat, chest pain, chills, nausea, and vomiting [4].
The incubation period for the illness, typically called COVID-19, is 1-14 days, with
dyspnea and pneumonia typically developing around 8 days from illness onset [5].
Olfactory and taste disorders have also been reported by some patients [6].
Approximately 40-50% of people infected with COVID-19 may be asymptomatic [7].
Neurological symptoms associated with COVID-19 infection are also frequently reported
[8]– [11]. But it remains unknown whether the infection causes long-lasting alterations
or damage in the brain. Such an effect could have a serious impact on the vulnerability of
the brain and trajectory of other neurological diseases. Furthermore, psychiatric
symptoms observed in COVID-19 patients that persist for a long time after recovery
necessitate periodic monitoring of psychiatric symptoms and psychosocial support and
treatments for survivors from the acute to chronic stages [10]. In this thesis, we begin to
assess the microscopic tissue integrity of the brain in-vivo using advanced diffusion
tensor imaging (DTI) methods with 2mm isotropic voxel, following COVID-19 infection
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with ultra-high-field 7 Tesla MRI scanner and the association of these changes in the
brain with long-term cognitive and neuropsychological dysfunction.
The way in which people experience COVID-19 infection varies significantly from
individual to individual. Based on the cohort study by Cummings and colleagues, 67% of
critically ill patients were men [5]. Men over 60 years of age with co-morbidities were at
higher risk of developing severe respiratory symptoms that needed hospitalization or that
led to death while most young people and children had milder symptoms or were
asymptomatic [5]. Hypertension and diabetes mellitus were the most common comorbidities among hospitalized COVID-19 patients [12]. The experience and severity of
symptoms also varies in association with different SARS-CoV-2 variants.
In patients admitted to hospital bilateral multi lobar ground-glass opacity in the lungs was
the most common radiologic features in their chest computed tomography (CT) [4].
Although SARS-CoV mostly affects the upper respiratory tract, SARS-CoV-2 can also
target cells in the lower airway [13]. Ground-glass opacity (GGO) describes areas of hazy
increased lung opacity through which the vessels and bronchial structures can still be
seen. In most patients, marked lymphopenia has been observed, which is similar to what
has been observed with other coronaviruses and it is particularly severe in non-survivors.
COVID-19 infection leads to a high production of cytokines by white blood cells
compared to other health conditions [14]. Patients admitted to ICU may have very high
levels of cytokines caused by a cytokine storm [13]. In men over the age of 68 there is a
higher risk of respiratory failure, acute cardiac injury and heart failure that leads to death,
regardless of any history of cardiovascular disease [15]. As of the writing of this thesis,
there have been 6 waves [16] associated with the COVID-19 pandemic in Ontario,
Canada. Several different variants of the SARS-CoV-2 virus have been encountered,
each with slightly different symptom profiles and severity.
Although the virus most commonly affects the respiratory system, it can affect any organ
in the human body. The virus is an RNA virus, consequently replication can take several
days to reach viral loads high enough to damage organs [17]. The virus binds to
angiotensin converting enzyme 2 (ACE2) receptors in tissue membranes of most organs
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including vascular endothelial cells, lung, heart, brain, kidneys, intestine, liver, and
pharynx and can directly injure theses organs or cause systemic disorders or organ
malfunction [13]. The ACE2 receptor is present in mucosa as well allowing the virus to
enter the body through the eyes, nose, and mouth [18]. Coagulation disturbances and
damage to vascular endothelium can contribute to multiple organ injury long after acute
infection and lead to chronic injury. SARS-CoV-2 damages endothelial cells in organs
and causes diffuse lymphocytic endothelitis which can lead to vasoconstriction [19]. The
cytokine storm induced by the virus can also lead to a systemic inflammatory response
syndrome (SIRS), acute respiratory distress syndrome (ARDS), multiple organ injury,
shock, and death [14]. Beyond inflammation, hypercoagulability, and edema can also
cause hypoperfusion and lead to organ ischemia [20]. Although primarily considered a
respiratory virus, infiltration of the SARS-CoV-2 virus into the brain can produce a
number of neurological symptoms.

1.5.1

COVID-19 Infections in CNS

Many viruses can enter the human central nervous system (CNS) [21]. Among these,
coronaviruses not only target the respiratory tract but may also invade the CNS and cause
neurological disease, which has been documented for almost all coronaviruses including
severe acute respiratory syndrome coronavirus (SARS-CoV) [22]. It is still unknown
whether the potential neuro invasion of SARS-CoV-2 has a direct effect on the acute
respiratory failure of some COVID-19 patients [23].
Many patients with severe respiratory symptoms also have neurological symptoms that
many be due to viral RNA-induced neural inflammation, or stroke triggered by
coagulation, or impaired brain clearance. Although the most common symptoms of
SARS-CoV-2 infection are respiratory in nature, some patients develop neurological
symptoms including headache, nausea, vomiting, and loss of taste or smell. Neurological
manifestations can also include impaired consciousness and delirium providing further
evidence that the virus can spread to the human neocortex in the brain [24]. In fact, the
presence of viral-like particles in the frontal tissue and capillary endothelium has been
confirmed by electron microscopy [24]. SARS-CoV has been reported to infect the brain
in both human and animal experimental studies [23]. Moreover, some coronaviruses
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spread through a synapse-connected pathway to the medullary cardiorespiratory center
from receptors in the lung and lower respiratory airways [23].
It has been suggested that a hematogenous route is the most probable pathway for the
virus to enter the brain [9], [24]. The lymphatic drainage system in the brain that contains
olfactory/cervical lymphatic vessels could also be an entry of SARS-CoV-2 to the brain
[9]. ACE2 is present in the cerebral cortex and brain stem neurons and plays a role in the
regulation of physiological functions including cardiovascular, metabolic, neurogenesis,
and stress response [25]. Since ACE2 is expressed in the olfactory epithelium, the virus
may enter the brain through axons of the olfactory bulb neurons under the cribriform
plate [23]. The taste and smell disturbances that have been reported by some COVID-19
patients suggests olfactory bulb involvement in the illness. Based on the similarity
between SARS-CoV-2 and previous coronaviruses responsible for respiratory syndromes
including the Middle East respiratory syndrome (2012) and the severe acute respiratory
syndrome epidemic (2003), it has been suggested that COVID-19 could be neuroinvasive
[23]. In addition, there is evidence of edema and degeneration of neurons in the brain
autopsy of patients with SARS [26]. Also, meningitis and encephalitis have been reported
in some patients with COVID-19 infection, illustrating viral invasion of the CNS [14].

1.5.2

Neurological Manifestation in COVID-19 Patients

Since the beginning of the pandemic there has been concern that some COVID-19
survivors may be at a higher risk of neurological complications based on previous studies
of other coronaviruses [27]. Neurological complications have been reported in previous
respiratory syndrome pandemics [28], [29] during the acute phase of illness directly
through viral infection or indirectly from the accompanying cytokine storm, or due to a
post-infectious immune system response [30].
In addition to respiratory symptoms, neurological manifestations have been reported in
COVID-19 patients including CNS, peripheral nervous system (PNS), and skeletal
muscular injury manifestation [30].

CNS symptoms include dizziness, headache,

impaired consciousness, acute cerebrovascular disease, ataxia, and seizure.

PNS

symptoms include taste and smell impairment, vision impairment and nerve pain. It is
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worth mentioning that CNS symptoms were more common than PNS symptoms in
COVID-19 patients [31]. Some of these neurological symptoms are non-specific such as
headache, myalgia, and altered mental status while some are more specific syndromes
that need urgent care [31]. These neurological symptoms may be explained by the
presence of ACE2 in the nervous system and skeletal muscle [18]. Brain autopsies of
patients with COVID-19 showed hyperemic and edematous brain tissue and some
neuronal degeneration [32].
Most neurological manifestations occur in the early stages of the illness [31] and it has
been shown that ischemic stroke can happen approximately two weeks after the onset of
the illness [33]. Based on a study performed in the United States, the loss of taste or
smell as a common symptom in COVID-19 infection, is more likely from the infection
rather than other sequences of the infection [34].
Impaired consciousness varies from change of consciousness level such as somnolence,
stupor, and coma to consciousness content such as confusion and delirium. Early
diagnosis could prevent cross-infection, neurological injuries, and death especially in
some patients that don’t have typical symptoms such as fever, cough and diarrhea and
come to the hospital with only neurological symptoms. Acute cerebrovascular disease
including ischemic stroke and cerebral hemorrhage can be diagnosed by clinical
symptoms and head CT. Diagnosis of seizure is based on clinical symptoms at the time of
presentation. Skeletal muscle injury is when a patient experiences skeletal muscle pain
and elevated serum creatine kinase levels [31].
Laboratory findings in patients with CNS symptoms have shown lower lymphocyte and
platelet counts and higher blood urea nitrogen levels compared to patients without CNS
symptoms which suggests immune suppression in patients with CNS symptoms,
especially those with severe infection. In patients with less severe illness there were no
significant differences in laboratory results between the patients with and without CNS
symptoms [31]. Comparing lab findings of the patients with and without peripheral
nervous system (PNS) symptoms in both severe and non-severe COVID-19 patients, did
not show any significant difference [31].
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Patients with skeletal muscle damage had higher level of creatine kinase regardless of the
severity if their illness. They also had higher neutrophil counts and lower lymphocyte
counts, which are representative of increased inflammatory and blood coagulation
responses.

The elevated proinflammatory cytokines in serum that cause some

abnormalities in the nervous system may also be the source of some skeletal muscle
damage [32].
D-dimer protein levels may represent how severe an infection is and might help to
identify patients that are high risk of pulmonary complications and venous
thromboembolism [35]. The D-dimer protein is a fibrin degradation product in the blood
produced when a blood clot is degraded by fibrinolysis. The D-dimer concentration can
help to diagnose pulmonary embolism and disseminated intravascular coagulation (DIC)
in clinical practice [31]. A previous study of COVID-19 patients found the D-dimer
levels were high in patients with muscle damage and severe infections, which may be the
reason why patients with severe infection are more susceptible to cerebrovascular
disease. Patients with muscle damage also had multiple organ damage including liver and
kidney abnormalities [31].
Several studies have proposed that coronaviruses may also relate to CNS diseases such as
multiple sclerosis and acute disseminated encephalomyelitis [36]. Multiple sclerosis
(MS) is defined by patches of demyelination and inflammatory cell infiltration [37].
Coronavirus-like particles were found at autopsy in the brain tissue of MS patients [38] as
well as human coronavirus RNA [39]. Also, in murine models, coronaviruses cause a
chronic demyelination condition which looks like MS [40].
Acute disseminated encephalomyelitis (ADEMS) is a demyelination disease that invades
the CNS and affects primarily children and young adults. It is detected on T1-weighted
MR images as white matter hyperintensities in the brain and spinal cord. The symptoms
in children include diffuse encephalopathy, seizures, optic neuritis, hemiparesis, and
other symptoms supporting spinal cord transection. The disorder generally occurs as a
para- or postinfectious process. Although there has been a report of a possible relation
between COVID-19 infection and ADEM, there is no clear evidence of the relationship
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between the infection agent and demyelination onset [40]. An experimental study in
mice did show a relationship between coronaviruses and CNS demyelination [41] but
supporting evidence of the relationship between the virus and demyelination in humans
[40] is limited. Ann Yeh E et al. reported a case of a demyelination disease in a child
with a positive PCR result for human coronavirus (HCoV) in cerebral spinal fluid and
nasopharyngeal specimens.
Brain imaging findings in hospitalized COVID-19 patients include ischemic infarct,
hemorrhages, and multiple patterns of leukoencephalopathy [31], [33]. There is also
evidence that patients with acute lung injury are more prone to develop brain injury
through hypoxemia and/or proinflammatory mediators between both the brain and the
lung [42], [43].

1.5.2.1

Specific Neurological Complications

Beside non-specific neurological symptoms such as headache, fatigue and altered mental
status in COVID-19 patients, more specific neurological symptoms have been also
reported. Al-Ramadan and colleagues completed a literature review on the acute and
post-acute neurological complications of COVID-19 illness which is summarized below
[44].

1.5.2.1.1

Cerebrovascular Disease

The human cerebrovascular system includes arteries and veins that circulates blood flow
to and from the brain. The carotid arteries and jugular veins are the main blood vessels in
the brain and any occlusion or rupture in these vessels interferes with blood perfusion of
the brain which could cause stroke with neurological deficits [45]. Stroke has been
reported in several studies of COVID-19 patients. Some of the patients had hemiplegia
with no medical history of comorbidities [46]. In a study by Beyrouti et al., characteristic
features of ischemic stroke have been described that showed large vessel occlusion in all
patients and hypercoagulation in most patients. It is interesting that one of the patients
had a stroke at the initial phase of the illness [47]. Ischemic stroke and hemorrhagic
stroke were reported in another case series in Italy in which patients with severe illness
developed stroke and some of them died or suffered from severe neurological disabilities
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[48]. Notably, in an assessment of the severity of acute ischemic stroke in the Global
COVID-19 Stroke Registry, patients with COVID-19 had a higher chance of developing
severe illness in comparison to healthy people [49].

1.5.2.1.2

Subarachnoid Hemorrhage

The subarachnoid space is the area between the arachnoid layer and the pia mater which
contains CSF. Bleeding into the subarachnoid space is a critical medical condition and is
called subarachnoid hemorrhage. Although not very common, some cases of
subarachnoid hemorrhage have been reported in COVID-19 patients [50][51].

1.5.2.1.3

Encephalopathy

Acute encephalopathy is acute impairment of brain function that is clinically present as
an altered consciousness level [52]. Many forms of encephalopathy have been reported as
clinical features of COVID-19 illness. It is interesting that encephalopathy could happen
at the early stage of the illness or even as an initial symptom [53]. Several imaging
methods can detect encephalopathy caused by COVID-19 illness including non-contrast
CT scan and electroencephalography, which is the most commonly used technique.

1.5.2.1.4

Acute Hemorrhagic Necrotizing Encephalopathy

Acute necrotizing encephalopathy (ANE) is a type of encephalopathy that usually occurs
after a febrile illness that is associated with a viral infection. Neurological manifestation
of ANE includes multifocal symmetric lesions in the brain on CT scans or MR imaging
[54]. ANE has been reported in COVID-19 patients with preliminary symptoms of cough,
fever and altered mental status and the MRIs showed hyperintensity in bilateral medial
temporal lobe and thalami [55].

1.5.2.1.5

Encephalitis

Acute viral encephalitis is a complication caused by a viral infection. Primary viral
encephalitis is caused by the invasion and replication of the virus in the brain, while
postinfectious encephalitis is mostly immune mediated [56]. The neurological
complications of the disease include altered consciousness, confusion, hallucination,
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aphasia, and abnormal movement. Hemorrhage, enhancement, or restriction of diffusion
have been reported in MR images of such patients [57]. Encephalitis has been diagnosed
in COVID-19 cases [44], [58], [59].

1.5.2.1.6

Meningitis/Encephalitis

Meningitis is the inflammation of the meninges which is the protective layer of the brain
and spinal cord. Bacterial or viral infection of the CSF within the meningeal layer causes
the inflammation. Meningitis and encephalitis have been reported in some severe
COVID-19 patients [44], [60].

1.5.2.1.7

Demyelinating Disorders

Any condition that causes damage to the myelin sheath of the nervous system is called
demyelination. Myelin is the protective layer surrounding nerves in the brain, optic nerve,
and spinal cord. The damage can slow down or stop the impulses between nerves and
cause neurological disorders. A wide range of demyelinating disorders have been
reported in the literature in COVID-19 patients including Guillain-Barre Syndrome and
Miller Fisher Syndrome that are autoimmune diseases where the immune system attacks
the nerves and causes muscle weakness and paralysis in some cases. Although the first
case of Guillain-Barre Syndrome associated with COVID-19 was not conclusive, over
time, with more hospitalized COVID-19 patients in different studies the evidence has
mounted. Male and elderly patients are the most affected group with acute, inflammatory,
demyelinating poly-radiculomyelopathy [44], [61]. Miller Fisher Syndrome, a variant of
Guillain-Barre Syndrome, has also been observed [62].

1.5.2.1.8

Central Nervous System Demyelination

Headache, anosmia, and dysgeusia are common symptoms of COVID-19 illness in the
early stage of the disease. Brain MRI results confirmed newly demyelinating lesions in
some COVID-19 patients [44], [63].
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1.5.2.1.9

Seizures

Although seizures are not a direct effect of the infection in COVID-19 patients that have
never had any previous brain injury or epilepsy, acute seizures are possible in some
patients. The seizures have different factors such as cortical irritation as the result of
blood brain barrier (BBB) breakdown due to the cytokine storm secondary to the viral
infection [64]. Based on previous studies on SARS-coronaviruses, accumulation of proinflammatory cytokines such as interleukin-8 (IL8) and monocyte chemoattractant
protein-1 (MCP1) could promote blood brain barrier breakdown. MCP1 is expressed in
CNS cells and is transiently up-regulated during inflammation that cause BBB
degradation [65].

Despite Epileptic seizures, non-Epileptic seizures (NES) are not

caused by unusual electrical activity in the brain, and both have the same symptoms. A
case of COVID-19 illness has been reported with NES as an initial symptom of the
illness [66].

1.5.3

Neurological Side Effects Associated with COVID-19
Treatment

In the literature review by Al-Ramadan and colleagues, possible neurological side effects
of different treatments of COVID-19 illness were reviewed. From the beginning of the
pandemic, several treatments have been used to reduce the severity of the illness, reduce
mortality, and reduce hospitalization [44]. Both the virus and the treatment might cause
neurologic and psychiatric symptoms. Antiretroviral medications that are used to prevent
replication of the virus may have CNS and PNS effects. These effects are different in
severity and frequency based on the biological mechanism involved. For example,
Lopinavir-Ritonavir combination could cause neurotoxicity despite its low penetration
through the BBB. The combination could cause bilateral sensorineural hearing loss after
4 weeks of treatment with depressive symptoms [67].
Corticosteroids that inhibit immune responses to combat inflammation, could cause
memory dysfunction and cognitive impairment due to the presence of a large number of
corticosteroid receptors in the hippocampus [67]. Even high-dose short course
corticosteroid treatments in COVID-19 patients may cause delirium and mood change
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[68]. Although there is not clear evidence of any benefits associated with chloroquine,
this drug has been used to stop the cytokine storm in COVID-19 patients to prevent acute
respiratory distress syndrome (ARDS). The treatment can cause neuropsychiatric
symptoms varying from mild (mood lability, nervousness) to severe (psychosis, suicidal
tendency) and higher doses cause more severe complications [69].

1.5.4

Neuropsychiatric Complications of COVID-19 Illness

The high rate of psychiatric symptoms in acute COVID-19 patients is not surprising due
to the physiological and psychosocial effects of the human coronavirus disease. Due to
the CNS involvement of the virus and viral infection, psychiatric symptoms could
contribute to neuropsychiatric complications [73]. It worth mentioning that antiviral
medications that patients receive might also cause psychiatric problems. There is
evidence that chloroquine and steroids can induce psychiatric episodes [74], [75]. The
psychiatric complications observed in COVID-19 patients could be the result of all
factors mentioned above [76].
Alteration in mental status is more common in patients with severe infection who need
hospitalization especially those that need intensive care. These symptoms are prevalent in
older patients and might reflect latent neurocognitive degenerative disease which relates
to sepsis, hypoxia, and the use of different medications during treatment [77]. The
alteration of acute mental status and primary psychiatric diagnoses such as psychosis
were identified in a large group of COVID-19 patients [78]. Altered mental status
included changes in personality, behavior, cognition, or consciousness. These findings
cannot be extrapolated to patients with mild symptoms or people that were asymptomatic,
but it gives robust prospective on severe patients that need hospitalization [77].
Neurological and psychiatric outcomes of COVOD-19 were assessed in a six-month
retrospective cohort study [27]. The data showed that the incidence of neurological or
psychiatric complications was 33.6% among survivors with 12.8% representing a new
diagnosis. Most disorders were more common in severely ill patients, especially those
who were hospitalized [27] and COVID-19 survivors were at higher risk of developing
psychiatric issues [27], [79].

Approximately 43% of patients with neuropsychiatric
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disorders had new onset of psychosis, 26% had neurocognitive (dementia-like) syndrome
and 30% had other psychiatric disorder including catatonia and mania [77]. Experimental
data have also shown that 43.1% of COVID-19 patients have depressive symptoms and
40.2% suffer from mental illnesses [80], [81]. Anxiety disorders, insomnia and dementia
were also reported in COVID-19 patients [82]. Along the anxiety disorder spectrum,
adjustment disorders, generalized anxiety disorders, post-traumatic stress disorder
(PTSD) and panic disorder were common.
Patients hospitalized with COVID-19 infection with headache, anosmia, dysgeusia,
diarrhea and those who needed oxygen therapy had lower scores in memory, attention
and executive function subtests comparing to asymptomatic patients [83]. Patients who
had headache and clinical hypoxia also had lower scores in global cognitive index.
Patients with cognitive complaints at presentation had higher anxiety and depression [83].
Insomnia, aggressive behavior, delusion, and hallucinations have also been reported in
COVID-19 patients in the literature [84]. Based on a meta-analysis of psychiatric
symptoms of COVID-19 patients and survivors, almost all the psychiatric symptoms of
the illness were severe during acute phase of the illness and then relieved to mild to
medium during recovery, which suggest that acute stress reactions are the main
psychiatric complications in the acute stage and is transient [76].
There is evidence that hospitalized patients who have recovered from COVID-19 illness
still suffer from fatigue, muscle weakness, sleep difficulties, depression, and anxiety,
even six months after acute infection [85]. Therefore, monitoring the psychiatric
symptoms of COVID-19 patients after recovery and providing psychiatric consultations
and treatments are of great importance [76]. Furthermore, based on the mental health
continuum model, psychiatric symptoms may be early signs of mental disorders and the
more severe and lingering the symptoms are the greater chance of developing mental
disorders [86]. Consequently, timely diagnosis of mental health issues is vital in the
clinical management of COVID-19 patients and survivors [76].
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1.5.5

Post-Acute COVID-19 Syndrome

Post-acute COVID-19 syndrome describes lingering symptoms in patients after acute
infection and recovery that are persistent and debilitating. These symptoms are not
limited to hospitalized patients with severe acute infection. As reported by Tabacof et
al., patients who managed their illness without the need for hospitalization can also have
post-acute symptoms, which are challenging for both patients and healthcare teams. The
most prevalent persistent symptoms in the post-acute phase (more than 6 weeks after the
onset of acute symptoms) are fatigue (92%), loss of concentration/memory (74%),
weakness (68%), headache (65%), and dizziness (64%) [70]. These mainly neurological
symptoms can be either persistent symptoms or new symptoms that emerge after
recovery [44], [70]. In another study by Carfi et al., persistent symptoms were assessed
in discharged hospitalized patients around 60 days after the onset of the first COVID-19
symptoms. Only 12.6% of the patients did not report any COVID-19-related symptoms
and 87% of patients reported persistence of at least one symptom with fatigue and
dyspnea being the most common. It is worth mentioning that worsened quality of life was
reported among 44% of patients [71]. Another prospective cohort study of recovered
adult COVID-19 patients showed that half of COVID-19 survivors had post-acute
syndrome 10-14 weeks after the onset of their symptoms. Radiological and spirometric
alterations were observed in less than 25% of patients and were mild [72].

1.5.6

Brain Microstructural Changes in COVID-19 Patients

Magnetic resonance imaging (MRI) can be used to investigate brain structure,
microstructure, and function following COVID-19 infection. Changes in micro-structural
and functional integrity in recovered COVID-19 patients could suggest neuro-invasion of
SARS-CoV-2 [8]. Micro-structural changes in the CNS can be detected by diffusion
imaging methods, which may be more sensitive to tissue damage than gross structural
measurements.
Previous MRI findings following COVID-19 infection have been varied. In one study,
an enlarged volume of the central olfactory system including bilateral olfactory cortices
and hippocampi was observed [8]. This study also found a decrease in some diffusion
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tensor imaging (DTI) metrics (mean diffusivity (MD), axial diffusivity (AD), and radial
diffusivity (RD)) accompanied by an increase of fractional anisotropy (FA) within white
matter (WM) in recovered COVID-19 patients [8]. The decrease in MD values and
increase in FA suggest a greater alignment of fibers and restricted diffusion occurs after
infection [93]. The gray matter volumetric changes in the central olfactory system led to
speculation that the SARS-CoV-2 virus might enter the CNS through a neuronal
retrograde route [8]. The olfactory gyrus was recognized as the first functional area in the
CNS to be infected by SARS-CoV-2 [94]. It has also been suggested that various limbic
system components could be affected by infection due to a high ACE-2 expression [8].
Decreases in cortical thickness and cerebral blood flow (CBF) and changes in WM
microstructures were found to be more severe in patients with severe illness compared to
those with mild disease, especially in the frontal and limbic system and these changes
were significantly correlated with inflammatory markers [10].

1.6

Thesis Objectives

The overall goal of this thesis was to determine the incidence of brain imaging
abnormalities in COVID-19 survivors who experienced neurological symptoms and the
association of these brain injuries with long-term cognitive and neuropsychological
dysfunction. We performed an observational cohort study that examined patients after
they recovered from COVID-19 illness using the highest magnetic field strength
available in Canada for human brain MRI. Ultra-high field MRI increases sensitivity to
measure cerebral microbleeds, cerebral vascular integrity, and brain microstructural
abnormalities related to ischemic tissue damage.
We hypothesize that COVID-19 patients with neurological symptoms would have
impaired cognitive function associated with the number of microbleeds in the brain, the
presence of white matter hyperintensities, and tissue microstructural changes in
subcortical brain regions. When initially conceived, the primary endpoint for this cohort
study was focused on was the incidence of microbleeds and the secondary endpoints
included assessments of diffusion abnormalities and white matter hyperintensities.
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Understanding the impact of imaging changes in the brain on cognitive function could
allow patients to be managed more effectively, increasing their quality of life, and
relieving future impact on the healthcare system.
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Chapter 2

2

Examining the Association between Brain MRI
Measures at 7 Tesla and cognition following COVID-19
Infection

2.1 Introduction
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes a range of multisystemic symptoms and in severe cases can lead to respiratory failure and consequently
death [120]. As the number of people infected with the coronavirus disease of 2019
(COVID-19) increases, it has become evident that some patients experience prolonged
symptoms including fatigue, headache, weakness, dyspnea, sleep disturbance, and
cognitive impairments, well beyond the resolution of respiratory symptoms. When
symptoms last for more than 28 days after the initial onset of COVID-19 related
symptoms, the condition is referred to as post-acute COVID-19 syndrome or long
COVID [121]. Such longer-term complications have been observed in both hospitalized
patients and non-hospitalized patients who experienced less severe forms of acute
COVID-19 illness [122]. Long COVID symptoms may include several neurological
symptoms suggesting effects on the brain either directly or indirectly [123]. The presence
of the angiotensin converting enzyme-2 (ACE-2) receptor for the SARS-CoV-2 virus in
the brain and brain stem also suggests the possibility of direct effects from viral invasion
of the CNS [124]. However, a direct link between acute neurological symptoms and
long-term changes in cognition and brain microstructure has not been established.
The SARS-CoV-2 virus activates the immune system of the host and can produce a
cytokine response that leads to general inflammation [125]. Evidence also suggests that
the virus generates a process of neuroinflammation [125], [126]. Inflammation within the
brain can have both acute and long-term effects and may exacerbate neurodegenerative
processes [83]. Interestingly, the limbic system and its related structures, including the
hippocampi and basal ganglia, which are involved in cognitive processes such as
memory, attention, emotion, and perception, contain more inflammatory related enzymes
than do the primary motor or sensory cortices [127], [128]. Therefore, it is of particular
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interest to examine changes in these structures following COVID-19 infection. COVID19 infection may also be associated with a prothrombotic state and other coagulation
disorders [129], [130]. Increased microbleeds have previously been reported in COVID19 patients with severe symptoms usually requiring hospitalization [131], [132]. But it
remains unclear if microhemorrhages are related to COVID-19 infection or a more
general phenomenon associated with critical illness [133].
Several recent studies have highlighted the potential long-term health impact of COVID19 illness including fatigue, anxiety, post-traumatic stress disorder (PTSD), and deficits
in attention, mood, and memory [8], [16]– [19]. For example, in a systematic review and
meta-analysis of approximately 48000 patients from 14 to 110 days after viral infection,
the most common symptoms were fatigue (58%), headache (44%), attention disorder
(27%), hair loss (25%), and dyspnea (24%) [134]. Another study examining impairments
within 90 days of infection, found that the most common psychiatric disorders in
COVID-19 survivors without previous cognitive impairments were anxiety disorders,
including generalized anxiety disorders, post-traumatic stress disorder, and panic
disorders [82]. Furthermore, patients with neurological symptoms including headache,
anosmia, and dysgeusia had lower scores in memory, attention, and executive function
subtests compared to asymptomatic patients [83]. Similarly, in hospitalized COVID-19
survivors without brain lesions, a systemic immune-inflammation index predicted worse
depression and PTSD outcomes [135] almost 90 days after acute infection. Finally,
survivors discharged from the hospital had higher PTSD scores using the diagnostic and
statistical manual of mental disorders, fifth edition (DSM-5) [136] criteria than a control
group and the score correlated with the duration after discharge [11].
Neuroimaging has shed light on the anatomical correlates of cognitive impairments in
many neurological conditions [104]. Diffusion MRI specifically provides insight into
white matter (WM) connectivity and overall tissue microstructural integrity [137].
Diffusion tensor imaging (DTI) which is an extended form of diffusion-weighted
imaging, provides quantitative metrics that are sensitive to the movement of water within
tissue microstructures [104], [138]. Specifically, fractional anisotropy (FA) and mean
diffusivity (MD) are the two most common quantitative diffusion metrics. MD measures
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the mean water diffusion and is typically increased when cellular structures break down
resulting in an increase in free water diffusion [104]. FA measures anisotropic water
diffusion and reflects the degree of directionality of cellular structures, particularly within
white matter fiber tracts. However, the accuracy of FA values can be compromised in
tissue regions with crossing fibers since this metric is sensitive to the degree of
anisotropy as well as orientation dispersion [111]. More advanced diffusion MRI (dMRI)
metrics can overcome this limitation. For example, microscopic fractional anisotropy
(FA) was recently developed to quantify water diffusion anisotropy independent of
neuron fiber orientation [111], [139]. Similarly, diffusion kurtosis imaging (DKI) is an
extension of DTI and is independent of the spatial direction of cellular structures [113].
Specifically, linear kurtosis (Klin) is a non-specific parameter that is related to the
heterogeneity in the size and shape of cells [111]. Several previous studies have
examined DTI metrics using 3 Tesla MRI in sub-cortical structures in healthy individuals
[140] and different neurological diseases including Progressive Supranuclear Palsy [141],
Tourette syndrome [142], Parkinson’s disease [143], and amyotrophic lateral sclerosis
[144] among many others. However, FA is a very recently developed measurement that
has not yet been applied to study any of the above diseases or COVID-19. Although the
majority of brain imaging studies following COVID-19 infection have been performed on
conventional 1.5T or 3T MRI scanners [8], [11], [123], [145], [146], the use of ultra-high
field MRI (UHF-MRI) at magnetic fields  7T provides greater sensitivity to microbleeds
and higher signal-to-noise ratio (SNR) [97], [147], [148]. The advantages of high-field
MRI translate into images with greater resolution and contrast across a wide range of
neurologic disorders and psychiatric conditions [149].

UHF-MRI (e.g., 7T) has

previously been used to provide a comprehensive assessment of DTI and DKI parameters
in neurological conditions like amyotrophic lateral sclerosis (ALS) [150], however, 7T
MRI has yet to be applied to study brain changes following COVID-19 infection.
The long-term cognitive and neuropsychological effects of COVID-19 illness in
survivors with mild symptoms are still poorly understood. The current study examined
cognitive and neuropsychological changes approximately two months after infection and
the association of changes with advanced dMRI correlates within subcortical brain
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structures of the limbic system using 7T MRI. Specifically, we examined whether
specific cognitive, psychological, and diffusion metrics were linked to neurological
symptoms experienced during the acute phase of illness. We hypothesized that COVID19 survivors who experienced acute neurological symptoms would show impairments in
cognitive function associated with an increased number of microbleeds in the brain and
evidence of tissue microstructure damage within structures of the limbic system.

2.2
2.2.1

Materials and Methods
Study Design

This study was approved by the Western University Health Sciences Research Ethics
Board. This observational cohort study examined people who had recovered from the
respiratory symptoms of COVID-19 illness and had neurological symptoms during the
acute phase of illness. There was no randomization for this study. During a baseline visit,
conducted either in person or over the phone depending on COVID-19 restrictions, verbal
or written consent was obtained from each participant and demographic information,
medical/surgical history, and medications were documented.
The study included three separate additional sessions (Figure 2-1). Briefly, the second
session included two over-the-phone cognitive tests; the Telephone Interview for
Cognitive Status (TICS) and the telephone-based Montreal Cognitive Assessment
(MoCA-Blind). For the third visit, participants went to the Robarts Research Institute at
Western University to complete neuropsychological and cognitive testing as well as a 7T
MRI scan.

Cognitive testing was performed using the comprehensive Repeatable

Battery for Neuropsychological Status (RBANS) test administered by study staff [114],
while neuropsychological data were gathered using the patient-reported outcomes
measurement information system (PROMIS) American Psychiatric Association
Assessment Measures (APA), based on Section III of the DSM-5 self-report questionnaire
[151]. The Columbia Suicide Severity Rating Scale (CSSRS), a suicidal ideation and
behavior rating scale, was also administered to evaluate suicidal risk [152]. Patients were
asked if they had any previous head injuries. A brain MRI scan without contrast was
performed on a 7T MRI at Western’s Centre for Functional and Metabolic Mapping. The
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fourth and final 6-month follow-up assessment was performed by phone and included the
TICS and MoCA-Blind scales. An adverse event report was collected in each visit.
Research staff and participants abided by all COVID-19 infection public health
prevention requirements throughout the study.

Figure 2-1: Study Procedures and Schedule of Events

2.2.2

Participants

Sixty-three patients met the inclusion/exclusion criteria and were recruited from
southwestern Ontario between September 2020 and December 2021 at the
multidisciplinary virtual London Health Sciences Centre Urgent COVID-19 Care Clinic
(LUC3) in London, Ontario. The LUC3 clinic was designed to care for high-risk patients
with polymerase chain reaction (PCR) confirmed COVID-19. These patients were
referred to the clinic from the local public health unit, emergency department, recent
hospital admission, or from family physicians. High-risk patients included those over the
age of 40 and/or those over the age of 18 with pre-existing medical conditions (e.g.,
chronic respiratory illness) putting them at risk of hospitalization with severe COVID.
Study participants who reported a heavy burden of any neurologic symptom (headaches,
brain fog, anosmia, paraesthesia, etc.) were approached about participation in the study.
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Included patients were aged from 18 to 85 years with a confirmed diagnosis of COVID19 within the past six months. Participants must have had neurological symptoms during
the acute phase of illness and were free of COVID-19 respiratory symptoms for at least
one month. Participants were excluded if they had current respiratory symptoms
consistent with COVID-19 or if they have evidence of acute psychosis, pre-existing
dementia, or previous cognitive impairments. Subjects with contraindications to 7T MRI
(e.g., metal implants, claustrophobia, inability to lie still in the scanner, and pregnant or
breastfeeding women) were also excluded.

2.2.3

Neuropsychological Assessments

To assess long-term cognitive and neuropsychological impairments, a set of tests and
questionnaires were administered. The tests included the Repeatable Battery for
Neuropsychological Status (RBANS) with 12 subtests that measured five different
indices: the immediate memory index (list memory and story memory subtests), the
delayed memory index (list recall, list recognition, story recall, and figure recall subtests),
the visuospatial/constructional ability index (figure copy and line orientation subtests),
the attention index (digit span and coding subtests), and the language index (picture
naming and semantic fluency subtests) [114]. The raw scores from the RBANS subtests
were transformed into index scores according to the RBANS manual [114]. The RBANS
total scale was calculated from the score of these five index scores. The index scores
range from 40 to 160 within the age-adjusted normative data with a mean of 100 for each
index score and a SD of 15, where lower scores represent worse performance [114]. To
assess if neurocognitive status was impaired the procedure suggested by Girard et al
[153] and adapted for RBANS by Mitchell et al [154] was applied [146]. A trained
examiner administered the RBANS, which took approximately 20-30 minutes. For the
current study, participants were excluded from cognitive test analysis if English was not
their first language, because there are no normative values for people with English as
their second language. Participants then completed the American Psychiatric Association
assessment, DSM-5 PROMIS questionnaires that measure cross-cutting symptoms:
somatic symptoms (total raw score), sleep disturbance (T-score), depression (T-score),
anxiety (T-score), anger (T-score), PTSD, and acute stress disorder (average total score)
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[151]. Also, the Columbia Suicide severity rating scale (CSSRS) was administered by the
trained examiner after the DSM-5 measures [152]. All the tests were performed the same
day and prior to the MRI. This testing session lasted approximately one hour.

2.2.4

Magnetic Resonance Imaging

Brain magnetic resonance imaging was performed on a Siemens Magnetom 7T Plus MRI
scanner with a head-only gradient coil (80 mT/m strength and 400 T/m/s slew rate) and a
customized 8-channel transmit and 32-channel receive radio frequency (RF) coil
following the cognitive assessments as part of Visit 3. The MRI protocols (parameters
provided in Table 2-1) included high resolution anatomical T1-weighted MP2RAGE (700
m isotropic), fluid attenuated inversion recovery (FLAIR, 800 m isotropic), 3D time of
flight imaging (470 m isotropic), gradient echo (GRE) imaging to assess microbleeds
(0.1x0.1x1.3 mm3), and diffusion MRI (including FA, 2mm isotropic). MRI scans were
assessed by a blinded expert neuroradiologist to identify anomalies including
microbleeds, white matter hyperintensities, and other clinically relevant findings.
Table 2-1 : 7T MRI Protocols and acquisition parameters
MRI Sequence

Parameters

3D-magnetization-prepared rapid
gradient echo (MP2RAGE)

TR/TE=6000/2.74 ms; TI1=800 ms;
TI2=2700 ms; 1= 4; 2= 5; 0.7-mm
isotropic voxels
TR/TE/TI=9000/268/2600 ms; 0.8mm isotropic voxels
TR/TE=21/14 ms; Acceleration
factor=3; 80 slices; 30%
oversampling; 0.1x0.1x1.3mm voxels
TR/TE=6400/91 ms; 2-mm isotropic
voxels; 66 slices; acceleration
factor=2; Shell1: b-value 1000 s/mm2,
Shell 2: b-value 2000 s/mm2
TR/TE=12/3.59 ms; Acceleration
factor=3; 18.2% oversampling; 44
slices; 0.5-mm isotropic voxels

3D-T2-weighted fluid-attenuated
inversion recovery (FLAIR)
3D-multislice gradient echo (GRE)

3D-diffusion-tensor imaging (DTI)

3D-time of flight-angiography
(TOF)

Scan
Time
(min:s)
10:12

8:17
8:06

9:38

6:13
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Overall

42:26

TR  repetition time, TE  echo time, TI  inversion time,   flip angle

2.2.5
2.2.5.1

Diffusion MRI
Image Acquisition

The diffusion MRI (dMRI) sequence (Table 2-1) included linear and spherical b-tensor
encoding in the same acquisition, similar to previous work [108]. Linear encoding was
acquired in 2 shells, using 9 directions with b-value 1,000 s/mm2 and 24 directions with
b-value 2,000 s/mm2. Forty-two spherically encoded images were acquired; 30 images
with a b-value of 2,000 s/mm2 and 12 images with a b-value of 1,000 s/mm2. Five bvalues = 0 images and a reverse phase encoding b-value = 0 image were also acquired for
frequency drift and distortion correction respectively.

2.2.5.2

Processing

The raw diffusion data were corrected for Gibb’s ringing [155] and noise (via PCA
denoising) using the matrix3 package [156] , and eddy current [157], and distortion [158]
using the FSL package. The traditional diffusion metrics (FA and MD) were extracted
using the mrtrix3 package [159]. Finally, μFA was calculated by combining the linear fit
of the power averaged signal from linear and spherical encoding up to the second term of
the cumulant expansion [111].

2.2.5.3

Segmentation of Sub-Cortical Structures

Using the anatomical T1-weighted MP2RAGE images, the brain was extracted using the
FMRIB Software Library (FSL, Version 6) [160], and subcortical brain structures were
segmented [161]. Seven subcortical structures were segmented, including left and right
caudate, putamen, pallidum, hippocampus, accumbens, amygdala, and thalamus (Figure
2-2). FSL was used to measure the volume of each of the mentioned subcortical
structures.
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Figure 2-2: T1-weighted anatomical MP2RAGE images showing the subcortical regions
included in the current study: A: sagittal view, B: coronal view, C: axial view. 1: Brain
stem; 2: right thalamus; 3: left thalamus; 4: right caudate; 5: left caudate; 6: right putamen;
7: left putamen; 8: right pallidum; 9: left pallidum; 10: left hippocampus; 11: right
hippocampus; 12: right accumbens; 13: left amygdala.

The segmentation results were visually verified for each subject by overlaying the
segmented subcortical structures on the T1-weighted MP2RAGE brain extracted images
in the FSL viewer (Version 6). To create a mask of each structure that minimized the
inclusion of pixels with partial volume artifact around the edges, all structure edges were
eroded using a cube kernel in MATLAB (Version R2019b Update 3, The MathWorks,
Inc., USA). Based on the voxel counts, a threshold of 2000 voxels were used to apply
either a one voxel or two voxel erosion. Both the accumbens and amygdala contained
<2000 voxels and consequently were eroded by one voxel while all other subcortical
structures were eroded by two voxels (Figure 2-3).
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Figure 2-3: Description of the subcortical segmentation pipeline highlighting FA
diffusion MRI analysis within the caudate. A: T1-weighted axial image with subcortical
structures shown with colors corresponding to Figure 2. B: Corresponding FA map.
C: The corresponding T1-weighted anatomical image. D: Left caudate mask (white
pixels) and left caudate mask after 2 voxels erosion to minimize partial volume effect
(red pixels). E: the final left caudate mask used to calculate mean FA within the left
caudate, superimposed on the T1-weighted anatomical image.
The diffusion-weighted images (including maps of FA, FA, MD, Klin) were registered to
the T1-weighted anatomical MP2RAGE images using an affine registration (FLIRT) in
FSL. FLIRT is a fully automated, robust, and accurate tool for linear (affine) intra- and
inter-modal brain image registration with improved EPI to structural registration and
distortion-correction [162]. The eroded segments were used as masks to identify pixels
within each structure in the diffusion maps. All pixels contributing to a structure were
used to measure the mean, median, and standard deviation (SD) of each diffusion metric
within each sub-cortical region.

2.2.6

Statistical analysis

SPSS Statistics (V.27, International Business Machines, USA) was used for all analyses.
Descriptive statistics were generated to provide the minimum, maximum, mean, and SD
for the RBANS indices and the DSM-5 measures. A one-sample t-test (p-value<0.05 was
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considered significant) was performed to determine whether the mean values of the
participants performance for the six RBANS indices significantly differed from the mean
performance of the normative US population within the Battery (mean 100). The impact
of the neurological symptoms present during the acute phase of illness on long-term
cognitive performance and diffusion metrics was assessed by grouping participants into
two group: those with and those without specific symptoms. Comparisons were only
made for symptoms if groups contained at least ten subjects. Dependent variable values
were generally not normally distributed. Therefore, independent non-parametric Mann
Whitney U-tests were used to compare metrics between groups. Each diffusion metric
and symptom were considered a separate analysis because different participants were
included in the groupings of those with and without symptoms. A Bonferroni correction
was used to reduce the chance of a Type 1 error for each analysis due to the inclusion of
fourteen different regions (left and right for 7 brain regions). Therefore, the Bonferroni
adjusted p-value for this analysis was 0.05/14 = 0.0036. The normality of the data was
assessed using the Kolmogorov-Smirnov test. Non-parametric Spearman’s correlation
tests were used to assess associations between RBANS indices and diffusion metrics.
Since age is an important factor that can affect brain structure volumes, the relationship
between brain structure volumes and cognitive and diffusion metrics was assessed using a
partial correlation analysis, with age as a covariate. All statistical tests were two-sided.
For the correlation analyses, p-values <0.05 were considered significant.

2.3
2.3.1

Results
Demographic and Clinical Characteristics

Sixty-three participants who tested positive for SARS-CoV-2 were recruited between
September 2020 and December 2021. The MRI and neuropsychological testing at Visit 3
were performed with mean (13854) days from the onset of initial symptoms. Three
participants were excluded: one had MRI incompatible eyebrow microblading, one had
an MRI incompatible ear prosthetic, and one had a wire in their jaw. In addition, thirteen
participants did not complete the MRI portion of the study and were excluded from
imaging analyses: one participant did not fit into the scanner, four participants were
claustrophobic, and eight participants withdrew themselves from the study after the first
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phone visit. Two additional participants were excluded from diffusion MRI analyses
because these data were not acquired. Of the fifty-one patients who completed RBANS
(the four patients that were claustrophobic completed the RBANS but not the MRI), eight
spoke English as their second language (ESL) and were excluded from the analysis of
RBANS and other cognitive assessments. Medical histories of each participant were
collected at the first visit. Of the 45 participants included in the imaging analysis and the
43 participants included in the cognitive assessments, the mean age was (45  16) years,
and 76% were female.
In this study cohort, one patient (2%) required treatment in the intensive care unit (ICU),
two participants (4%) required oxygen (hypoxia), two participants (4%) had COVIDrelated pneumonia hospitalization, and one participant (2%) was hospitalized due to a
pulmonary embolism. The average hospital stay for these participants was seven days.
However, overall, the study cohort was predominantly composed of those labelled with
mild COVID illness. The clinical and demographic characteristics of the studied
population are presented in Table 2-2.
Table 2-2 : Clinical Symptom Frequency
Symptom
Headache
Brain fog
Change/loss of taste
or smell
Confusion
Fever
Chills
Peripheral
neuropathy
Anxiety
Fatigue
Decreased mood
Acute Stress
Disorders
PTSDa
Nausea
Diarrhea
Vomiting

Category

Percent

Males

Females

*

Neuro
Neuro
Neuro

93
93
69

12
12
09

32
31
23

Mean
Age
44.5
43.9
45.9

*
*
*
*

Neuro
Neuro
Neuro
Neuro

44
62
33
29

06
10
03
04

15
19
13
09

48.4
45.4
42.7
42.9

*
*
*
*

Psych
Psych
Psych
Psych

62
93
49
51

06
12
06
03

23
32
16
20

45.2
43.9
42.5
42.8

*
*
*
*

Psych
GI
GI
GI

56
56
58
27

04
07
10
02

22
20
18
10

40.6
46.2
48.0
45.9

39

Abdominal Pain
*
GI
36
08
09
Decreased
*
GI
53
09
16
appetite/oral intake
Dyspnea
Resp
82
10
30
Cough
*
Resp
71
10
24
Sore throat
Resp
20
05
06
Nasal congestion
*
Resp
38
02
16
Asthma
Resp
16
00
08
WMb hyperintensity
Imaging
53
08
17
Microbleeds
Imaging
11
02
03
a
Post-Traumatic Stress Disorders
b
white matter
* Indicates a symptom included in group analysis of diffusion MRI measures

53.5
42.8
46.4
48.6
38.0
39.9
45.4
48.7
37.6

The most common neurological symptoms (Table 2-2) experienced during the acute
phase of the illness in study participants were brain fog (93%), headache (93%),
change/loss of taste or smell (69%), fever (62%), and confusion (44%).

The most

frequent non-neurological symptoms (Table 2-2) included fatigue (93%), anxiety (62%),
PTSD (56%), decreased mood (49%), and acute stress disorder (51%).

2.3.2

MRI Clinical Interpretation

Forty-five participants completed the MRI scan. All scans were read by a blinded
neuroradiologist (Dr. Michael Jurkiewicz ) and findings are summarized in Table 2-3.
Eleven participants (24%, mean age of 55 years) showed abnormalities on the 3D T1weighted anatomical images that were possibly related to COVID infection. The most
common anatomical finding was supratentorial volume loss in six (13%) participants.
Patchy FLAIR hyperintensities were reported in 25 participants (53%), mainly in the
bilateral cerebral white matter: 4 participants (9%, mean age of 66 years) showed chronic
small vessels ischemic disease (SVID); 8 participants (18%, mean age of 60 years)
showed changes that were most likely SVID, and 7 participants (16%) had
hyperintensities in the bifrontal cerebral white matter, most commonly observed in
individuals with migraine. Of these participants only one patient had a previous clinical
history of chronic migraines. Four participants (9.3%) had foci of susceptibility effect on
the GRE images. Figures 2-4A and 2-4B shows examples of abnormally increased
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susceptibility in the GRE images of younger patients and Figures 2-4C, 2-4D, and 2-4E
show examples of FLAIR hyperintensities observed in three younger patients.
Table 2-3 : MRI Findings and Frequency
Findings

Percent Frequency

T1-weighted
Supratentorial volume loss
13.3
Hypo-intensity along right ventricle
2.2
Hyperintensity on left thalamus
2.2
GMa heterotopia along right ventricle
2.2
Focal outpouching from lateral ventricle
2.2
Developmental venous anomalies in anterior right and
2.2
left frontal lobe
FLAIRb
Chronic SVIDc
8.9
Hyperintensities in bilateral cerebral WM most likely
17.8
SVID
Hyperintensities in bilateral cerebral WM, SVID or
4.4
migraines
Hyperintensities in bilateral cerebral WM with frontal
15.6
predominance, most likely migraines
Hyperintensities in periventricular WM, demyelination
2.2
disease and ischemic
Single hyperintensity in deep frontal left WM
2.2
d
SWI
Developmental venous anomalies in frontal lobe
4.4
Abnormal susceptibility in left caudate head
2.2
Abnormal susceptibility in left superior temporal lobe
2.2
Abnormal susceptibility in right precentral gyrus
2.2
Abnormal susceptibility in left cerebral hemisphere
2.2
e
3D-TOF
Aneurysm
4.4
a
gray matter
b
fluid attenuation inversion recovery
c
small vessels ischemic disease
d
susceptibility weighted imaging
e
3D- time of flight angiography
f
For Frequency=1, an age range is provided to maintain anonymity

Mean
Agef

6
1
1
1
1
1

64
50-54
45-49
55-59
55-59
35-39

4
8

66.3
60.4

2

55.0

7

36.8

1

45-49

1

35-39

2
1
1
1
1

44.5
60-64
35-39
60-64
50-54

2

65.0
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Figure 2-4: Examples of WM hyperintensity and abnormal susceptibility. A: Axial GRE
(slice thickness 1.25mm) of a 35-39 year old man with a punctate focus abnormal
susceptibility on the left superior temporal gyrus; B: Axial GRE (slice thickness 1.25mm) of
a 35-39 year old woman with a developmental venous anomaly in the right anterior frontal
lobe; C: Axial FLAIR image (slice thickness 0.8mm) of an 18-24 year old woman D: Axial
FLAIR image (slice thickness 0.8mm) of a 35-39 year old woman; E: Axial FLAIR image
(slice thickness 0.8mm) of a 30-34 year old woman.

All three FLAIR images show

nonspecific foci of hyperintensities in the bilateral cerebral WM with frontal lobe
predominance commonly seen in patients with migraines.
maintain anonymity.

Age ranges are provided to
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2.3.3

Cognitive and Neuropsychological Evaluation

Forty-three patients were included in the assessment of cognitive performance and
neuropsychological evaluation. Descriptive statistics of the cognitive testing performed
in this cohort, including the DSM-5 PROMIS measures reported as T-scores and the
RBANS index scores are provided in Table 2-4.
Table 2-4 : Neuropsychological Characteristics
Characteristic

Minimum Maximum

Mean S.D

pValuec

tValued

Age
18.0
75
45.215.9
a
RBANS index
Immediate Memory
73.0
126
0.853
0.186
100.413.9
Visuospatial/Constructional
60.0
126
0.130
-1.543
96.016.7
Language
79.0
127
0.612
0.511
100.911.0
*
Attention
60.0
122
0.008
-2.773
93.914.4
Delayed Memory
48.0
125
0.548
-0.606
98.714.6
Total Scale
66.0
121
0.128
-1.554
97.012.7
DSM-5b T-score
Level 2-Somatic Symptoms
01.0
22
10.55.4
Level 2-Sleep Disturbance
35.9
76.5
57.59.0
Level 2-Depression
37.1
81.1
51.411.2
Level 2-Anxiety
36.3
75.8
54.011.0
Level 2-Anger
32.9
83.3
51.311.0
PTSD (NSESSS)
00.0
03
0.901.0
Acute Stress Disorder
00.0
03
0.900.80
(NSESSS)
Days between symptoms
53.0
252
139.554.4
onsets and cognitive
assessments/MRI
a
Repeatable Battery for the Assessment of Neuropsychological Status
b
Diagnostic and Statistical Manual of Mental Disorders,5th edition
c, d
Comparison of RBANS (one sample t-test) to normative data with mean = 100, df=42
*
p<0.05

A one-sample t-test was used to compare the mean performance of the studied population
across the six RBANS indices with the standard mean performance of the normative
population (10015) (Table 2-4). The group performed significantly worse in the
attention domain relative to the normative population (p=0.008). There was no significant
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correlation between the time interval between the onset of acute symptoms and cognitive
testing and the RBANS index scores. However, there was a moderate correlation between
education and immediate memory index score (p=0.002, R=0.45) and delayed memory
index score (p=0.014, R=0.37) (Table 2-5). Overall, according to Mitchell's definition for
RBANS [154], 81% of the population showed minimal cognitive impairments, 14% were
mildly/moderately cognitively impaired, and 5% were severely cognitively impaired.
(Table 6)
Table 2-5 : Correlations between RBANS Indices and Demographic Variables
RBANS Index

Immediate Memory
Visuospatial/Constructional
Language
Attention
Delayed Memory
Total Scale
*
P<0.05, Spearman’s Rho

Education

p-Value
0.002*
0.520
0.051
0.857
0.014*
0.030

R-Value
0.451
0.101
0.299
-0.028
0.371
0.332

Days between symptoms
onset and RBANS
Administration
p-Value
R-Value
0.769
0.046
0.107
0.250
0.330
0.152
0.065
0.284
0.357
0.144
0.090
0.261

Table 2-6 : Severity of Neuropsychological Symptoms
Neuropsychology Assessments
RBANS
DSM-5 Somatic symptoms
DSM-5 Sleep disturbance
DSM-5 Depression
DSM-5 Anxiety
DSM-5 Anger
NSESSS PTSD
NSESSS Acute stress disorder

Minimal
81.4%
7.8%
41.2%
62.8%
47.0%
70.6%
41.2%
45.1%

Mild/Moderate
13.9%
60.8%
47.0%
29.4%
43.1%
25.5%
47.0%
47.0%

Severe
4.6%
31.4%
1.8%
7.8%
9.8%
3.9%
11.8%
7.8%

The severity of various neuropsychological disturbances is summarized in Table 2-6
based on the DSM-5 measures [151]. Interestingly, the assessments showing the most
severe dysfunction were somatic symptoms (31.4% of the cohort), PTSD (11.8% of the
cohort), and anxiety (9.8% of the cohort). Similarly, the assessments showing the greatest
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prevalence of mild/moderate dysfunction were somatic symptoms (60.8% of the cohort),
PTSD (47% of the cohort), acute stress disorder (47% of the cohort), and sleep
disturbance (47% of the cohort). Depression and anger scores were least likely to be
affected with anger affecting 70.6% of the cohort minimally, and depression affecting
62.8% of the cohort minimally. Seven (16.3%) participants reported suicidal ideation
with no imminent plan or intent, mainly during their acute illness according to CSSRS
measures [152], and were referred for psychological services.
Patients were grouped based on the presence or absence of the symptoms reported during
the acute phase of their illness. Comparisons between neuropsychological measures,
cognitive measures, and imaging metrics were made between groups.

To ensure a

sufficient number of participants were included in each group, only clinical variables
with N  10 per group and a prevalence of 25%-75% were included in the analyses. For
this reason, headache, brain fog, fatigue, and dyspnea (Table 2-2) were excluded from
these analyses since most patients reported these symptoms, and sore throat and asthma
were present in less than 25% of the population.
Non-parametric Mann-Whitney U-tests were used to compare the mean values of
different cognitive and neuropsychological measures between the groups of participants
with and without specific symptoms (Table 2-7). Participants with PTSD (56%) had a
significantly (p<0.01) worse depression, anxiety, anger, and acute stress disorder DSM-5
scores than those without PTSD. Decreased mood was reported in 49% of the sample and
these participants also had significantly higher depression score compared to the group
without the symptom. Participants with nausea (56%) had a higher score in the DSM-5
somatic symptoms. The RBANS language index score was lower in the patients having
diarrhea (58%) compared to those without, and subjects with decreased appetite/oral
intake (53%) had significantly lower scores in RBANS visuospatial/constructional
abilities and total score. These cognitive findings remained significant after excluding the
six patients that required hospitalization during their acute illness.
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Table 2-7: Significant Neuropsychological Findings Related to Clinical
Characteristics
Symptoms / Subtests
Z-Value
p-Value
a
PTSD (N =26)
DSM-5 Depression
-3.16
0.002*
DSM-5 Anxiety
-3.22
0.001*
DSM-5 Anger
-2.60
0.009*
Acute Stress Disorder
-4.92
<0.001*
Decreased mood (N=22)
DSM-5 Depression
-2.62
0.009*
Nausea (N=27)
DSM-5 Somatic Symptoms
-3.09
0.002*
Diarrhea (N=28)
RBANS LGIb
-2.78
0.005*
Decreased appetite/oral
Intake (N=25)
RBANS VCIc
-3.41
<0.001*
d
RBANS TS
-2.69
0.007*
a
N refers to the numbers having the symptom
b
Language Index
c
Visuospatial/Construction Index
d
Total Score Index
*
P<0.05, independent Mann-Whitney U-test

2.3.4

Mean With

Mean Without

56.8
58.5
55.4
01.5

45.5
48.1
46.4
0.05

56.0

47.7

12.6

8.0

90.3

106.0

89.1
92.4

106.0
100.7

MRI Diffusion Changes Associated with Cognitive
Performance

Non-parametric partial correlation with age as a covariate was used to examine
associations between diffusion metrics in subcortical structures, subcortical structure
volumes, and cognitive assessments. Although significant correlations were detected with
some RBANS indices, the R-values were low (Table 2-8). Therefore, no strong
correlations were observed between diffusion measures and cognitive assessments.
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Table 2-8 : Correlation between RBANS and Diffusion Metrics
Subcortical
Structure
Hippocampus
La-Hipp-MD

RBANS Index

Attention
Total Scale

p -Value

R-Value

0.037*
0.029*

-0.331
-0.345

Thalamus
L-Thal-FA
Language
0.013*
L-Thal-Klin
Language
0.037*
b
R -Thal-Klin
Language
0.019*
Accumbens
Immediate Memory
0.035*
L-Accu-FA
a
Left
b
Right
*
P<0.05, partial correlation with age used as a covariate

2.3.5

0.391
0.330
0.368
0.334

MRI Diffusion Differences Associated with Neurological
Symptoms

Subcortical volumetric analysis showed a moderate correlation between left and right
caudate volume, left thalamus volume, and left and right putamen volume and age (Table
2-9).

However, there were no differences in subcortical structure volumes when

grouping participants by the presence of symptoms.
Table 2-9 : Correlation Between Age and Subcortical Volume
Subcortical Structure
Volume
L-Caud-Volume
R-Caud-Volume
L-Thal-Volume
L-Puta-Volume
R-Puta-Volume
*
P<0.01, Spearman’s Rho

Age
p-Value
0.003*
0.003*
0.004*
0.008*
0.005*

R-Value
-0.458
-0.448
-0.435
-0.411
-0.431

Non-parametric Mann-Whitney U-tests revealed several differences in advanced
diffusion measures within subcortical structures when comparing groups with and
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without symptoms (Table 2-10). Considering the caudate nucleus, we found higher FA
associated with diarrhea. In the thalamus, lower MD was associated with chills. In the
putamen, higher Klin were associated with diarrhea. Higher Klin and FA were associated
with nasal congestion in the pallidum. In the amygdala, higher FA was associated with
nasal congestion and in the accumbens nucleus lower FA was related to cough (Figure 25).
Table 2-10 : Diffusion MRI findings related to clinical characteristics
Subcortical
Structure
Caudate
R-Caud-FA
Thalamus
L-Thal-MD
Putamen
L-Puta-Klin
Pallidum
R-Pall-FA
R-Pall-Klin

Symptom

Diarrhea

N

26

ZValue

pValue

-3.03

0.002*

Mean
With
0.40

Mean
Without
0.33

Chills

15

-3.35

<0.001*

0.00080

0.00088

Diarrhea

26

-3.63

<0.001*

1.22

1.04

Nasal Congestion
Nasal Congestion

17
17

-3.06
-3.46

0.002*
<0.001*

0.89
2.05

0.81
1.77

<0.001*

0.54

0.37

0.001*

0.38

0.55

Amygdala
Nasal Congestion
17
-4.03
L-Amyg-FA
Accumbens
L-Accu-FA
Cough
32
-3.23
*
p<0.01, Independent samples Mann-Whitney U-test
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Figure 2-5: Significant diffusion MRI findings in subcortical structures related to
symptoms present at the time of acute illness
There was a negative moderate partial correlation between diffusion metrics and onset
days (Table 2-11) when controlling for age in right thalamus FA, and right amygdala
FA and a positive correlation in left caudate Klin mean values. It should be noted that all
the reported cognitive and imaging findings remained significant after excluding the six
patients that required hospitalization at the onset of their illness.
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Table 2-11: Partial correlation between Diffusion Metrics and Onset Days
Subcortical
Structures

Days between onset of symptoms and MRI

p-Value
L-Caud-Klin
0.006*
<0.001*
R-Thal-FA
0.007*
R-Amyg-FA
*
p<0.01, age was used as a covariate

2.4

R-Value
0.423
-0.522
-0.418

Discussion

The long-term neuropsychological and cognitive effects of COVID-19 illness are still
poorly understood. In the current study we examined the impact of COVID-19 illness on
cognitive function approximately 8 weeks after infection and used 7T MRI to measure
tissue microbleeds and changes in water diffusion metrics within subcortical brain
structures of the limbic system associated with specific symptoms. The study cohort
included people with predominantly mild COVID illness who reported neurological
symptoms at the time of acute illness. They had measurable attention deficits compared
to a normative population on average 53 days after the initial respiratory symptoms of
COVID-19. The most prevalent radiological finding observed in 22 of 43 participants
was white matter hyperintensities observed on FLAIR, consistent with those frequently
attributed to small vessel disease and migraine. Evidence of abnormal susceptibility in
GRE images indicative of microbleed was observed in four of 43 participants. Several
changes in diffusion MRI metrics were observed within subcortical structures when
grouping participants according to the presence and absence of specific symptoms. The
presence of chills was associated with changes in MD in the thalamus.

Diarrhea (GI

symptom) was associated with diffusion metric changes in the caudate and putamen.
Finally, the presence of nasal congestion and cough (respiratory symptoms) was
associated with diffusion metric changes in the pallidum, accumbens, and amygdala.
There was a weak correlation between attention scores and MD in the hippocampus. All
cognitive and imaging findings remained significant after excluding the six participants
that required hospitalization at the onset of their illness.
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The deficit in attention observed on average 53 days from the onset of symptoms in this
study cohort is consistent with previous studies on COVID survivors that have shown
attention and concentration dysfunction between 10-35 days after hospital discharge [83],
85 days from recovery [163] and 60 days from recovery [164]. The time interval between
the onset of acute symptoms did not correlate with cognitive performance. The most
severe dysfunction observed in the current study were somatic symptoms (31.4%), PTSD
(11.8%), and anxiety (9.8%). In participants experiencing PTSD, depression, anxiety,
anger, and acute stress disorder scores indicated worse symptoms compared to the group
without PTSD. Also, patients having decreased mood during their illness were at higher
risk of depression compared to the group without decreased mood. PTSD, anxiety, and
depression were previously reported to be significantly higher in COVID-19 survivors
[11], [83]. Two participants had severe cognitive impairment, six participants had mild or
moderate cognitive impairment, and 35 participants did not have any cognitive
impairment (Table 2-6). Since the two participants with severe cognitive impairment
were young (<40 years old) and there were no overall changes in cognition (RBANS total
scale), or association between the length of time between symptom onset and cognitive
testing, the impaired cognition detected in these participants may be attributable to the
infection.
The most common neurological symptoms during the acute phase of the illness were
brain fog (93%), headache (93%), change/loss of taste or smell (69%), fever (62%), and
confusion (44%) and the most frequent non-neurological symptoms included fatigue
(93%), anxiety (62%), PTSD (56%), decreased mood (49%), and acute stress disorder
(51%). These findings are consistent with previous reports of fatigue, and problems with
attention, anxiety, mood, and memory, as well as post-traumatic stress disorder (PTSD)
following COVID-19 illness [8,11-14,28].
Interestingly, patients with gastrointestinal symptoms (e.g., diarrhea, nausea, vomiting
and abdominal pain) during their acute illness had worse performance in some cognitive
domains in the current study. This effect could be explained by the link between the
gastrointestinal tract and the brain through the established gut-brain axis [125]. COVID19 neuro-invasion may occur through the gut-brain axis via the enteric nervous system,
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which is regulated by the vagus and symptomatic nerves and by the presence of ACE2
receptors in the enterocytes of the small intestine and colon [125], [165]. Those with
diarrhea performed worse in the RBANS language domain, and those with decreased
appetite/oral intake performed worse in the RBANS visuospatial/constructional abilities
and total score. These cognitive findings remained significant after excluding the six
patients that required hospitalization during their acute illness.
Radiologic evaluation of the MR images suggested that this cohort of COVID-19
survivors had white matter hyperintensities bilaterally in cerebral WM that were
consistent with SVID in older subjects or previous history of migraines or COVIDinduced migraines in younger subjects. The SARS-CoV-2 virus can produce
neuroinflammation [125], [126], which plays an important role in the pathophysiology of
migraines [166]. In participants with frontal lobe WM hyperintensities only one reported
a previous history of chronic migraines.

Therefore, we hypothesize that COVID

infection might induce migraine-like symptoms in younger patients consistent with the
headaches that patients experienced during their acute illness (headache was present in
93% of participants in the current study). Intra-axial susceptibility suggestive of
microvascular pathology, ischemic and macro hemorrhagic manifestations have been
previously reported in severe COVID cases [167]. In the current cohort abnormalities on
GRE images consistent with microbleeds were noted in four of 43 patients (9.3%), which
is less frequent than previous studies. One explanation for this discrepancy is that the
participants in the current study were more mildly affected compared to the more
severely ill patients included in previous studies. Specifically, only one participant
required ventilation in the current study.
The volume of sub-cortical structures did not differ when comparing groups of
participants with and without specific symptoms. There was a moderate correlation
between left and right caudate volume, left thalamus volume, and left and right putamen
volume and age. Although not observed in the current study, previous studies have
shown volume changes in subcortical structures associated with gastrointestinal
symptoms associated with irritable bowel syndrome (IBS), one of the most widely
diagnosed disorders of gut-brain interaction [168]. For example, in one study patients
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with diarrhea-predominant IBS had enlarged thalamus and caudate nucleus volumes and
altered hemispheric asymmetries of these two structures [169]. In other studies, patients
with vomiting had significantly lower volume of the right caudate and patients with chills
had significantly lower volume of the left hippocampus [169], [170].
Tissue microstructural integrity in subcortical structures was assessed using diffusion MR
imaging metrics. All structures except the hippocampus showed some changes in
diffusion metrics associated with either neuropsychological, gastrointestinal, or
psychiatric symptoms. It is unknown whether these microstructural alterations are due to
the direct effect of the virus (neuroinvasion) or caused by a systematic reaction [125]. It
was previously hypothesized that CNS neuroinvasion by SARS-CoV-2 could occur
across the BBB or the blood-cerebrospinal fluid barrier at the choroid plexus, or through
nerve routes such as the olfactory nerve, trigeminal nerve, gut-brain axis, or vagus-nerve
[125], [171]. Follow-up studies will be needed to assess the longer-term impact of these
observed change.

It is noteworthy that MD in the hippocampus was moderately

correlated with attention and total RBANS scale, FA and Klin in the thalamus were
moderately correlated with language, and FA in the nucleus accumbens was moderately
correlated with immediate memory. These changes observed across several subcortical
structures suggest that subtle changes in several regions are contributing to different
cognitive functions (Table 2-8).
One of the changes in the brain that occurs with aging is an increased presence of iron
that can be identified with DTI. A previous study showed that both diffusion anisotropy
and mean diffusivity were higher in an older group compared to a younger group in the
caudate and putamen, while the thalamus showed a minor effect of age on anisotropy or
diffusivity [172]. The current study showed a negative moderate partial correlation
between diffusion metrics and the number of days to the onset of symptoms when
controlling for age in right thalamus FA, and right amygdala FA and a positive
correlation with left caudate Klin mean values. This result suggests that some diffusion
metrics may be changing as a function of time following infection.
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2.5

Strengths and Limitations

The participants in the current study, selected from the LUC3 clinic in London, Ontario,
had a confirmed diagnosis of COVID-19 infection and the referral criteria for the clinic
were very broad (i.e. anyone 40+, or 18-39 with a comorbid condition). As a result, the
population seen in clinic were representative of the overall COVID population in
Ontario/Canada.

The 7T neurological MRI scans were read by an experienced

neuroradiologist Dr. Michael Jurkiewicz and the neurocognitive assessments were
performed by a single trained rater and monitored by an experienced psychometrist and
neurologist. Although the RBANS was initially developed for the assessment of
dementia, the use of this assessment has been validated for screening neurocognitive
status in a younger population with mild cognitive impairment [114]. However, RBANS
is a brief battery and does not cover all aspects of cognition [146]. The use of ultra-high
field 7T MRI in this study allowed the acquisition of diffusion MRI data to detect
microstructural changes in the brain tissue with higher resolution than is typically used on
clinical systems. The study also incorporated recently developed FA measurements to
increase sensitivity. The greatest limitations of the current study are the absence of
baseline MRI, relatively small sample size and the lack of control groups who were
infected with a different influenza virus or a healthy group. Without such controls it is
difficult to confirm that the observed white matter hyperintensity and susceptibility
changes are due specifically to the SARS-CoV-2 infection. However, since the white
matter lesions observed in the current study had a very high prevalence (>50%) and were
observed in many young participants, it is likely that the SARS-CoV-2 infection
contributed to their development. The clinical impact of these changes is currently
unknown.

2.6

Conclusions

The extent of neuroinvasion or changes in the brain following COVID-19 infection in
relation to long COVID-19 is poorly understood. In this study, we assess the microscopic
tissue integrity of the brain in-vivo using advanced diffusion tensor imaging (DTI)
methods following COVID-19 infection with ultra-high-field 7 Tesla MRI and the
association

of

these

changes

in

the

brain

with

long-term

cognitive

and
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neuropsychological dysfunction. Results showed that the group performed significantly
worse in the attention domain compared to the normative population. White matter
hyperintensities on FLAIR images were the dominant radiographic finding and suggests
that further follow up to assess the impact on neurological and neuropsychological
disorders later in life may be beneficial. Differences in advanced diffusion metrics within
several subcortical structures when comparing groups with and without symptoms also
suggest subtle tissue changes in these regions may contribute to cognitive dysfunction
following infection.
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Chapter 3

3

Objectives, Conclusion, and future direction
3.1

Objectives

The overall goal of this thesis was to determine the incidence of brain imaging
abnormalities in COVID-19 survivors who experienced neurological symptoms and the
association of these brain injuries with long-term cognitive and neuropsychological
dysfunction. We performed an observational cohort study that examined patients after
they recovered from COVID-19 illness using the highest magnetic field strength
available in Canada for human brain MRI. Ultra-high field MRI increases sensitivity to
measure cerebral microbleeds, cerebral vascular integrity, and brain microstructural
abnormalities related to ischemic tissue damage.
We hypothesize that COVID-19 patients with neurological symptoms would have
impaired cognitive function associated with the number of microbleeds in the brain, the
presence of white matter hyperintensities, and tissue microstructural changes in
subcortical brain regions. When initially conceived, the primary endpoint for this cohort
study was focused on was the incidence of microbleeds and the secondary endpoints
included assessments of diffusion abnormalities and white matter hyperintensities.
Understanding the impact of imaging changes in the brain on cognitive function could
allow patients to be managed more effectively, increasing their quality of life, and
relieving future impact on the healthcare system.
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3.2

Conclusion

In this thesis we aimed to detect brain structural abnormalities including microbleeds and
cerebrovascular changes in COVID-19 survivors after recovery and associate these brain
abnormalities with long-term cognitive and neuropsychological dysfunction using ultrahigh field 7 Tesla MRI. We assessed microscopic tissue integrity of the brain using
advanced diffusion MRI (dMRI) methods.
To determine if cognition is impaired in our sample, we used the RBANS battery that
includes normative data for the analysis. The results showed that the population
performed significantly worse in attention domain compared to the normative data in
RBANS (p=0.008). We also examined if there was any association between the onset day
of acute symptom and day of performing cognitive assessments but there were no
significant correlations observed. Our study showed that 81% of the cohort included
showed minimal cognitive impairments, 14% were mildly/moderately cognitively
impaired, and 5% were severely cognitively impaired. The most severe dysfunctions
were somatic symptoms, PTSD, and anxiety. Similarly, somatic symptoms, PTSD, acute
stress disorder and sleep disturbance caused mild/moderate dysfunction in the population.
All these neuropsychological findings necessitate further follow up with COVID-19
survivors to prevent complications later in life and increase their quality of life.
The dominant MRI finding in this cohort were white matter hyperintensities on FLAIR
images and some of the patients showed susceptibility changes on GRE. We grouped
patients based on the presence of specific symptoms and our results demonstrated
differences in advanced diffusion MRI metrics within subcortical and limbic system
structures between the group with and without symptoms.
Based on our findings of both cognitive and imaging assessments we suggest that these
subtle brain tissue changes may contribute to the cognitive dysfunction following the
infection. However further follow-up is needed in larger studies to determine whether
these changes resolve or place the brain at increased risk for neurodegenerative disease in
the future.
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3.3

Future direction

The greatest limitations of this study were the small sample size and the lack of control
groups either infected with a different influenza virus or a healthy group. Future studies
should include control groups to compare the imaging and cognitive findings with to
confirm that the observed results are due to SARS-CoV-2 infection. Currently, there are
several larger scale imaging studies being conducted in different parts of the world (e.g.
England, Canada), that could also provide either relevant control groups, or a means to
answer some of the questions raised by the current study. However, none of these studies
are performed at ultra-high magnetic fields. The use of ultra-high magnetic fields does
provide some advantages including greater image resolution and sensitivity to
microbleeds. However, because of the limited number of such MRI scanners available
worldwide, large scales studies using such technology is not possible at this time.
This thesis was focused on the quantitative analysis of diffusion metrics withing
subcortical structures. However, there is additional data available that has not yet been
examined.

For example, the MRI sequences included angiography and chemical

exchange saturation transfer (CEST) imaging that could provide additional insights into
brain changes following SARS-CoV-2 infection. In addition, diffusion metrics within
specific white matter tracts could also be examined and related to cognitive changes.
These data may provide information that could be used to generate hypotheses that could
be tested using the larger cohort datasets that are currently being acquired around the
world.
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